MY161103A - 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents - Google Patents

5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents

Info

Publication number
MY161103A
MY161103A MYPI2012001104A MYPI2012001104A MY161103A MY 161103 A MY161103 A MY 161103A MY PI2012001104 A MYPI2012001104 A MY PI2012001104A MY PI2012001104 A MYPI2012001104 A MY PI2012001104A MY 161103 A MY161103 A MY 161103A
Authority
MY
Malaysia
Prior art keywords
salts
nicotinamide
trifluoro
dichloro
ethoxy
Prior art date
Application number
MYPI2012001104A
Other languages
English (en)
Inventor
Roever Stephan
Wright Matthew
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY161103A publication Critical patent/MY161103A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2012001104A 2009-09-11 2010-09-08 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents MY161103A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11

Publications (1)

Publication Number Publication Date
MY161103A true MY161103A (en) 2017-04-14

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012001104A MY161103A (en) 2009-09-11 2010-09-08 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents

Country Status (34)

Country Link
US (1) US8227491B2 (OSRAM)
EP (1) EP2475645B1 (OSRAM)
JP (1) JP5604520B2 (OSRAM)
KR (1) KR101382871B1 (OSRAM)
CN (1) CN102639506B (OSRAM)
AR (2) AR078352A1 (OSRAM)
AU (1) AU2010294277B2 (OSRAM)
BR (1) BR112012005511B8 (OSRAM)
CA (1) CA2771493C (OSRAM)
CL (1) CL2012000611A1 (OSRAM)
CO (1) CO6491033A2 (OSRAM)
CR (1) CR20120089A (OSRAM)
CY (1) CY1114377T1 (OSRAM)
DK (1) DK2475645T3 (OSRAM)
EC (1) ECSP12011723A (OSRAM)
ES (1) ES2423821T3 (OSRAM)
HR (1) HRP20130869T1 (OSRAM)
IL (1) IL217920A (OSRAM)
IN (1) IN2012DN00763A (OSRAM)
MA (1) MA33563B1 (OSRAM)
MX (1) MX2012002254A (OSRAM)
MY (1) MY161103A (OSRAM)
NZ (1) NZ597514A (OSRAM)
PE (1) PE20120863A1 (OSRAM)
PL (1) PL2475645T3 (OSRAM)
PT (1) PT2475645E (OSRAM)
RS (1) RS52987B (OSRAM)
RU (1) RU2541475C2 (OSRAM)
SG (1) SG179035A1 (OSRAM)
SI (1) SI2475645T1 (OSRAM)
TW (1) TWI412363B (OSRAM)
UA (1) UA107088C2 (OSRAM)
WO (1) WO2011029827A1 (OSRAM)
ZA (1) ZA201201599B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
BRPI0609685A2 (pt) 2005-04-06 2010-04-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
RU2454405C2 (ru) * 2006-10-04 2012-06-27 Ф.Хоффманн-Ля Рош Аг Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина

Also Published As

Publication number Publication date
AR078352A1 (es) 2011-11-02
PL2475645T3 (pl) 2013-12-31
IL217920A (en) 2015-11-30
IL217920A0 (en) 2012-03-29
US8227491B2 (en) 2012-07-24
TW201114427A (en) 2011-05-01
BR112012005511B1 (pt) 2021-03-02
PE20120863A1 (es) 2012-07-23
ZA201201599B (en) 2012-11-28
KR20120048040A (ko) 2012-05-14
NZ597514A (en) 2013-10-25
CN102639506A (zh) 2012-08-15
CR20120089A (es) 2012-03-22
AU2010294277B2 (en) 2015-07-09
IN2012DN00763A (OSRAM) 2015-06-26
CA2771493C (en) 2017-08-29
EP2475645A1 (en) 2012-07-18
HRP20130869T1 (hr) 2013-10-25
RU2541475C2 (ru) 2015-02-20
CO6491033A2 (es) 2012-07-31
MA33563B1 (fr) 2012-09-01
AU2010294277A1 (en) 2012-02-09
MX2012002254A (es) 2012-03-16
ES2423821T3 (es) 2013-09-24
RU2012113924A (ru) 2013-10-20
HK1172021A1 (en) 2013-04-12
WO2011029827A1 (en) 2011-03-17
DK2475645T3 (da) 2013-07-22
CA2771493A1 (en) 2011-03-17
AR114032A2 (es) 2020-07-15
TWI412363B (zh) 2013-10-21
BR112012005511B8 (pt) 2021-05-25
PT2475645E (pt) 2013-08-05
SG179035A1 (en) 2012-04-27
SI2475645T1 (sl) 2013-10-30
CL2012000611A1 (es) 2012-09-07
RS52987B (sr) 2014-02-28
CN102639506B (zh) 2014-09-03
ECSP12011723A (es) 2012-04-30
US20110065759A1 (en) 2011-03-17
CY1114377T1 (el) 2016-08-31
BR112012005511A2 (pt) 2016-04-19
JP5604520B2 (ja) 2014-10-08
EP2475645B1 (en) 2013-07-03
KR101382871B1 (ko) 2014-04-08
UA107088C2 (xx) 2014-11-25
JP2013504534A (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
MX2013002660A (es) Heteroarilmetilamidas.
SG179035A1 (en) 5- (3,4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nicotinamide and salts thereof as hdl cholesterol raising agents
IN2012DN01233A (OSRAM)
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
IN2012DN02968A (OSRAM)
IN2014KN01075A (OSRAM)
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
WO2010142766A3 (en) Pyrimidine derivatives as zap-70 inhibitors
SG10201900504XA (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
MX2011010359A (es) Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2014001862A (es) 5-cicloalquil-o 5-heterociclil-nicotinamidas.
MX2011011618A (es) Agentes terapeuticos 713.
MX2013004126A (es) Compuestos n-piridin-3-ilo o n-pirazin-2-il carboxamida.
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
PH12012501476A1 (en) Aminoquinoline derivatives
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2014001860A (es) Hidrazidas del acido 3-piridin carboxilico como agentes elevadores del colesterol de lipoproteina de alta densidad (hdl).
MX2014002141A (es) Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o.
WO2012072791A3 (en) 2-(1-phenyl-4,5,6,7-tetrahydro-1h-indazol-4-yl)ethylamine derivatives useful as sigma receptor inhibitors